SAB Biotherapeutics, Inc. (SABS:NASDAQ) closed at $2.84 on October 23, 2026, down 6.58% on the day. The stock trades 44.9% below its 52-week high of $5.15 and 16.4% above its 52-week low of $2.44. Over the past year, it lost 6.3%. SAB Biotherapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, SABS closed higher on 112 days (44%). Its best day was June 15, 2026 (+17.12%) and its worst was December 8, 2025 (-10.80%). The stock moved 10% or more in a single session 5 times.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company advancing a class of immunotherapies based on its human polyclonal antibodies. It develops fully human antibodies produced from transchromosomic (Tc) bovine herds targeted at addressing specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer.
Find more stocks like SABS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.